98%
921
2 minutes
20
Gastric cancer is the fifth most common cancer worldwide and its incidence is rising. Surgery is the only curative strategy and its association with perioperative chemotherapy is now standard treatment for most resectable tumors. Despite treatment advances, disease relapse is high, even in early stages, and continued improvement in curative treatment is imperative. With deeper knowledge of gastric cancer heterogeneity, molecular subtypes, and the tumor immune microenvironment, new standard treatment strategies may emerge in the near future. This paper provides a comprehensive review of the current treatment landscape in resectable gastric cancer and future perspectives for the next decade regarding new agents such as targeted therapies, immunotherapy, antibody-drug conjugates, and the combination of multiple treatment modalities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11640278 | PMC |
http://dx.doi.org/10.3390/cancers16234036 | DOI Listing |
Eur J Gastroenterol Hepatol
August 2025
Department of Medical and Surgical Sciences, University of Bologna.
Background: Gastric cancer epidemiology evolved rapidly in the last century, shifting from being one of the main causes of cancer-related death to the sixth in high-income countries.
Methods: We conducted a narrative review on gastric cancer epidemiology. Our review focused on trends of gastric cancer and its relationship with Helicobacter pylori infection; cardia and noncardia gastric cancer risk factors; early onset gastric cancer; second primary cancers in patients with gastric cancer; and implementation of gastric cancer prevention strategies.
PLoS One
September 2025
Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, China.
Objective: To evaluate the burden and trends of digestive system cancers in adolescents and young adults (AYAs) globally between 1990 and 2021.
Methods: Data were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (1990-2021). We analyzed global, regional, and national disease burdens by calculating the age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) for AYAs.
Appl Biochem Biotechnol
September 2025
Operating Room, Shanghai Tianyou Hospital, No.528, Zhennan Road, Putuo District, Shanghai, 200331, China.
Gastric cancer (GC) is a malignant tumor originating from the epithelial cells of the gastric mucosa. The 5-methylcytosine (mC) modification refers to the addition of a methyl group to the fifth carbon atom of cytosine in RNA molecules. This study aimed to investigate the role of NOL1/NOP2/SUN domain (NSUN)6 in GC and its underlying molecular mechanisms.
View Article and Find Full Text PDFGastric Cancer
September 2025
Department of Gastroenterological Surgery, Hyogo Medical University, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Int J Surg
September 2025
The Japanese Society of Gastroenterological Surgery, Tokyo, Japan.
Background: The association between preoperative liver function and short-term outcomes after gastrointestinal cancer surgery is unknown. This study investigated the impact of Child-Pugh score-based preoperative liver dysfunction on short-term outcomes after distal gastrectomy and right hemicolectomy.
Materials And Methods: We included patients who underwent distal gastrectomy for gastric cancer or right hemicolectomy for colon cancer between 2018 and 2022 from the Japanese National Clinical Database.